Previous 10 | Next 10 |
Summary Global growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adj...
Summary Having suffered through a sharp decline in earnings multiples, SMID cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings t...
Summary Equities continued their slide during the third quarter, as investors grew increasingly anxious over the combination of aggressive interest rate increases and a growing likelihood of recession. Health care proved an impediment to relative performance, as the evaporation of...
Avantor, Inc. (AVTR) Q3 2022 Results Earnings Conference Call October 28, 2022, 08:00 AM ET Company Participants Christina Jones - Vice President of Investor Relations Michael Stubblefield - President and Chief Executive Officer Thomas Szlosek - Executive Vice Pr...
Avantor, Inc. ( NYSE: AVTR ) shed ~11% on Friday morning after the life sciences company lowered its full-year guidance despite recording better-than-expected financials for Q3 2022. The company's net sales exceeded previous projections to reach $1.9B with ~1% YoY growth...
The following slide deck was published by Avantor, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Avantor, Inc. 2022 Q3 - Results - Earnings Call Presentation
Avantor press release ( NYSE: AVTR ): Q3 Non-GAAP EPS of $0.34 beats by $0.01 . Revenue of $1.86B (+1.6% Y/Y) beats by $10M . Adjusted net leverage reduced to 3.6X, down 0.6X year-to-date Operating cash flow of $258.3 million; free cash flow of $219.3 milli...
Avantor® Reports Third Quarter 2022 Results PR Newswire Net sales of $1.86 billion , increase of 1.2%; core organic net sales growth of 7.8% Net income of $167.0 million ; Adjusted EBITDA of $384.0 million Diluted GAAP EPS of $0.25 ; adjust...
Citi upgraded the life sciences company Avantor, Inc. ( NYSE: AVTR ) to Buy from Hold on Wednesday, arguing that a moderate disconnect between its valuation and fundamentals indicates an attractive entry point to the stock at the current levels. The analyst Patrick Donnell...
Summary West Pharmaceutical Services is a quality firm that is doing well right now. But this doesn't make the firm an attractive prospect, even if we assume that management's forecast for 2022 is accurate. Shares need to get cheaper if the business is to make for a compelling...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for AVTR on July 29, 2024 05:42AM ET. The previous analyst recommendation was Overweight. AVTR was trading at $25.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
Bogota Financial Corp. (BSBK) is expected to report for Q2 2024 Capital Product Partners L.P. (CPLP) is expected to report $0.17 for Q2 2024 Colgate-Palmolive Company (CL) is expected to report $0.87 for Q2 2024 ARCA biopharma Inc. (ABIO) is expected to report for Q2 2024 Barnes G...
Avantor® Reports Second Quarter 2024 Results PR Newswire Net sales of $1.70 billion , decrease of 2.4%; organic decline of 2.0% Net income of $93 million ; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14 ; adjusted EPS of $0.25 Op...